Jean-François Llitjos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jean-François Llitjos has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
Frédéric Pène
Hôpital Cochin AP-HP Paris France
3 shared publicationsEmmanuel Canet
Hôpital de la Cavale Blanche CHU et Université de Bretagne Occidentale Brest France
2 shared publications- Frédérique Schortgen
Réanimation et Surveillance Continue Adulte, Centre Hospitalier Intercommunal de Créteil, Créteil, France
2 shared publications Jean-Paul Mira
2 shared publicationsNicolas Weiss
Groupe Hospitalier Pitié-Salpêtrière Charles Foix AP-HP Paris France
2 shared publicationsStephan Ehrmann
CHU de Tours Tours France
2 shared publications
Latest Publications
- Open Access
- 16 January 2026
- Published by Elsevier in Annals of Intensive Care
- Vol. 16, 100016
Acute hYpErcapnic respiratory failure in The ICU: A multicenter prospective observational study - The YETI study
- 16 January 2026
- Published by Elsevier in Annals of Intensive Care
- Vol. 16, 100016
Open AccessAcute hYpErcapnic respiratory failure in The ICU: A multicenter prospective observational study - The YETI study
- Open Access
- 4 November 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (21) , 6545
Remdesivir for Patients Hospitalized with COVID-19 Severe Pneumonia: A National Cohort Study (Remdeco-19)
Background. Given the rapidly evolving pandemic of COVID-19 in 2020, authorities focused on the repurposing of available drugs to develop timely and cost-effective therapeutic strategies. Evidence suggested the potential utility of remdesivir in the framework of an early access program. REMDECO-19 is a multicenter national cohort study assessing the ability of remdesivir to improve the outcome of patients hospitalized with COVID-19. Methods. We conducted a retrospective real-life study that included all patients from the early access program of remdesivir in France. The primary endpoint was the clinical course evolution of critically ill and hospitalized COVID-19 patients treated with remdesivir. Secondary endpoints were the SOFA score evolution within 29 days following the admission and mortality at 29 and 90 days. Results. Eighty-five patients were enrolled in 22 sites from January to April 2020. The median WHO and SOFA scores were respectively reduced by two and six points between days 1 and 29. Improvement in the WHO-CPS and the SOFA score were observed in 83.5% and 79.3% of patients, respectively, from day 10. However, there was no effect of remdesivir on the 90-day survival based on the control cohort for hospitalized COVID-19 patients with invasive ventilation. Conclusions. SOFA score appeared to be an attractive approach to assess remdesivir efficacy and stratify its utilization or not in critically ill patients with COVID-19. This study brings a new clinical benchmark for therapeutic decision making and supports the use of remdesivir for some hospitalized COVID-19 patients.
- 4 November 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (21) , 6545
Open AccessRemdesivir for Patients Hospitalized with COVID-19 Severe Pneumonia: A National Cohort Study (Remdeco-19)
Background. Given the rapidly evolving pandemic of COVID-19 in 2020, authorities focused on the repurposing of available drugs to develop timely and cost-effective therapeutic strategies. Evidence suggested the potential utility of remdesivir in the framework of an early access program. REMDECO-19 is a multicenter national cohort study assessing the ability of remdesivir to improve the outcome of patients hospitalized with COVID-19. Methods. We conducted a retrospective real-life study that included all patients from the early access program of remdesivir in France. The primary endpoint was the clinical course evolution of critically ill and hospitalized COVID-19 patients treated with remdesivir. Secondary endpoints were the SOFA score evolution within 29 days following the admission and mortality at 29 and 90 days. Results. Eighty-five patients were enrolled in 22 sites from January to April 2020. The median WHO and SOFA scores were respectively reduced by two and six points between days 1 and 29. Improvement in the WHO-CPS and the SOFA score were observed in 83.5% and 79.3% of patients, respectively, from day 10. However, there was no effect of remdesivir on the 90-day survival based on the control cohort for hospitalized COVID-19 patients with invasive ventilation. Conclusions. SOFA score appeared to be an attractive approach to assess remdesivir efficacy and stratify its utilization or not in critically ill patients with COVID-19. This study brings a new clinical benchmark for therapeutic decision making and supports the use of remdesivir for some hospitalized COVID-19 patients.
- Open Access
- 1 January 2021
- Published by Elsevier in Annals of Intensive Care
- Vol. 11 (1) , 97-170
Proceedings of Reanimation 2021, the French Intensive Care Society International Congress
- 1 January 2021
- Published by Elsevier in Annals of Intensive Care
- Vol. 11 (1) , 97-170
Open AccessProceedings of Reanimation 2021, the French Intensive Care Society International Congress
- Open Access
- 21 September 2020
- Published by Springer Nature in Critical Care
- Vol. 24 (1) , 1-4
Aminoglycosides for the treatment of septic shock: a propensity-based study
- 21 September 2020
- Published by Springer Nature in Critical Care
- Vol. 24 (1) , 1-4
Open AccessAminoglycosides for the treatment of septic shock: a propensity-based study
- Open Access
- 10 January 2017
- Published by Elsevier in Annals of Intensive Care
- Vol. 7 (1) , 105-207
Proceedings of Réanimation 2017, the French Intensive Care Society International Congress
- 10 January 2017
- Published by Elsevier in Annals of Intensive Care
- Vol. 7 (1) , 105-207
Open AccessProceedings of Réanimation 2017, the French Intensive Care Society International Congress
- Open Access
- 19 January 2016
- Published by Elsevier in Annals of Intensive Care
- Vol. 6 (1) , 1-6
Ilio-psoas hematoma in the intensive care unit: a multicentric study
- 19 January 2016
- Published by Elsevier in Annals of Intensive Care
- Vol. 6 (1) , 1-6
Open AccessIlio-psoas hematoma in the intensive care unit: a multicentric study
- Open Access
- 1 January 2016
- Published by Elsevier in Annals of Intensive Care
- Vol. 6 (1) , 23-9
Hyperoxia toxicity after cardiac arrest: What is the evidence?
- 1 January 2016
- Published by Elsevier in Annals of Intensive Care
- Vol. 6 (1) , 23-9
Open AccessHyperoxia toxicity after cardiac arrest: What is the evidence?
- 3 April 2013
- Published by Elsevier in Annales de Cardiologie et d'Angéiologie
- Vol. 63 (2) , 99-101
AIDS-related primary cardiac lymphoma with right-sided heart failure and high-grade AV block: Insights from magnetic resonance imaging
- 3 April 2013
- Published by Elsevier in Annales de Cardiologie et d'Angéiologie
- Vol. 63 (2) , 99-101
AIDS-related primary cardiac lymphoma with right-sided heart failure and high-grade AV block: Insights from magnetic resonance imaging